TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25089881

Group type: EXPERIMENTAL
Intervention: Dimension cues indicating the relevant stimulus dimension (e.g., 'number')
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mapping cues providing information regarding both the relevant task identity and its category-to-key mapping (e.g., 'one three')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incongruent Stroop condition (name ink color of incongruent color names, high control demand)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral Stroop condition (name color patches, low control demand)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermixed conditions of dimension cues and mapping cues
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermixed conditions of incongruent and neutral Stroop stimuli
Number of subjects: 0
Study: 21421689

Group type: EXPERIMENTAL
Intervention: Dual task balance training (strength and balance training while performing cognitive tasks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Strength and balance training only (control group)
Number of subjects: 43
Study: 20105610

Group type: EXPERIMENTAL
Intervention: Initial laparoscopic appendectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Initial nonoperative management (intravenous antibiotics with percutaneous drainage followed by interval laparoscopic appendectomy)
Number of subjects: 40
Study: 17284750

Group type: EXPERIMENTAL
Intervention: Watercress supplementation (85 g raw watercress daily for 8 weeks)
Number of subjects: 60
Study: 16124970

Group type: EXPERIMENTAL
Intervention: HA-coated tibial components
Number of subjects: 16

Group type: COMPARATOR
Intervention: Uncoated tibial components
Number of subjects: 16
Study: 11972998

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 100 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10442377

Group type: EXPERIMENTAL
Intervention: UFT (300 to 400 mg/day for 2 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UFT (600 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UFT (300 mg/day)
Number of subjects: 0
Study: 8560358

Group type: EXPERIMENTAL
Intervention: Urovac bladder evacuator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ellik evacuation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Toomey syringe
Number of subjects: 0
Study: 2207297

Group type: EXPERIMENTAL
Intervention: Recainam (oral doses 54-208 mg kg-1 in mice)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recainam (oral doses 25-110 mg kg-1 in rats)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recainam (oral doses 50-100 mg kg-1 in rabbits)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recainam (i.v. doses 1-15 mg kg-1 in rhesus monkeys)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recainam (oral doses 6-60 mg kg-1 in dogs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recainam (400-800 mg in humans)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recainam (single or multiple doses in dogs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recainam (i.v. doses in rats and rabbits)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recainam (i.v. doses in dogs, rhesus monkeys, and humans)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recainam (in humans)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recainam (in rhesus monkeys)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recainam (in laboratory animals and humans)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recainam (in rodents, rabbits, dogs, rhesus monkeys, and humans)
Number of subjects: 0
Study: 6456034

Group type: EXPERIMENTAL
Intervention: Continuous mass nylon suture with tight compression
Number of subjects: 302

Group type: COMPARATOR
Intervention: Continuous mass nylon suture with normal tension
Number of subjects: 302
Study: 30900152

Group type: EXPERIMENTAL
Intervention: Topically-administered haemocoagulase (batroxobin)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal Saline (control)
Number of subjects: 30
Study: 27837415

Group type: EXPERIMENTAL
Intervention: Sexual intercourse 3-4 times/week with symptomatic treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Symptomatic treatment only (control group)
Number of subjects: 56
Study: 25885280

Group type: EXPERIMENTAL
Intervention: 35 mg risedronate orally, once a week for 6 months postoperatively
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 23313145

Group type: EXPERIMENTAL
Intervention: Treatment for prescription opioid dependence
Number of subjects: 0
Study: 21360300

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SRIH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 0
Study: 19665588

Group type: COMPARATOR
Intervention: Standard paper record (PR)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: PDA with dietary and physical activity software (PDA)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: PDA with the same software plus a customized feedback program (PDA + FB)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Retention rate for the first cohort
Number of subjects: 210
Study: 19139391

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 1124

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 1124

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 1124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1124
Study: 16086932

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/d
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 12118485

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (Transamine)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 9925129

Group type: EXPERIMENTAL
Intervention: Mushrooms (C. tubaeformis) providing 14 microg ergocalciferol/d
Number of subjects: 27

Group type: COMPARATOR
Intervention: Ergocalciferol supplement providing 14 microg/d
Number of subjects: 27

Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 27
Study: 7538881

Group type: EXPERIMENTAL
Intervention: 23-gauge needle
Number of subjects: 123

Group type: COMPARATOR
Intervention: 27-gauge needle
Number of subjects: 123
Study: 2150642

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 282069

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 9
Study: 30366043

Group type: EXPERIMENTAL
Intervention: Minimally invasive cystectomy
Number of subjects: 4760
Study: 27265880

Group type: EXPERIMENTAL
Intervention: Mirabegron (50 mg per day) for 8 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Imidafenacin (0.2 mg per day) for 8 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Imidafenacin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Mirabegron
Number of subjects: 70
Study: 24980414

Group type: EXPERIMENTAL
Intervention: Circumcision plus antibiotic, anti-inflammatory, and α-blocker therapy
Number of subjects: 774

Group type: COMPARATOR
Intervention: Control group (medications only, no circumcision)
Number of subjects: 774
Study: 23577702

Group type: EXPERIMENTAL
Intervention: Negative, stereotypical images of obese targets
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Positive, nonstereotypical images of obese targets
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: African American female obese targets
Number of subjects: 1251

Group type: COMPARATOR
Intervention: Caucasian targets
Number of subjects: 1251
Study: 21562092

Group type: EXPERIMENTAL
Intervention: High-MUFA (HM) diet
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Low-fat (LF) diet
Number of subjects: 448

Group type: COMPARATOR
Intervention: High-SFA (HS) diet
Number of subjects: 448
Study: 19235739

Group type: EXPERIMENTAL
Intervention: Olfactory training (12 weeks, twice daily exposure to four odors: phenyl ethyl alcohol, eucalyptol, citronellal, eugenol)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No olfactory training (control group)
Number of subjects: 56
Study: 17008974

Group type: EXPERIMENTAL
Intervention: Orbofiban (oral glycoprotein IIb/IIIa inhibitor)
Number of subjects: 10392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10392

Group type: EXPERIMENTAL
Intervention: Orbofiban
Number of subjects: 10392
Study: 14711021

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study: 10761167

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg PO QD for 10 days
Number of subjects: 24
Study: 8826769

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Music video intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Rest period control group
Number of subjects: 96
Study: 1443245

Group type: EXPERIMENTAL
Intervention: Nortriptyline and interpersonal psychotherapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo maintenance conditions
Number of subjects: 73

Group type: COMPARATOR
Intervention: Nortriptyline conditions
Number of subjects: 73
Study: 6364909

Group type: EXPERIMENTAL
Intervention: Chenodiol, 375 mg/d
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 30678674

Group type: EXPERIMENTAL
Intervention: Problem-solving cognitive behaviour therapy (PSCBT) plus treatment as usual (TAU)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 22
Study: 30052729

Group type: EXPERIMENTAL
Intervention: Avelumab 10mg/kg by intravenous infusion every 2 weeks
Number of subjects: 371

Group type: COMPARATOR
Intervention: Physician's choice of chemotherapy (paclitaxel 80mg/m2 on days 1, 8, and 15 or irinotecan 150mg/m2 on days 1 and 15)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Physician's choice of chemotherapy
Number of subjects: 371
Study: 27334658

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID (open-label)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Adalimumab 40 mg every 2 weeks (blinded)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Tofacitinib 10 mg BID (blinded)
Number of subjects: 233
Study: 25294104

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) training towards smoking cues
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) training away from smoking cues
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control training (CBM)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Transfer task (modified Stroop test of smoking‐related cognitive bias)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Subjective mood and cigarette craving
Number of subjects: 72
Study: 23627026

Group type: EXPERIMENTAL
Intervention: Kurarinol (600 mg intravenous drip once a day for one month, followed by 200 mg oral capsule three times a day)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Silybin meglumine tablet (same dosage as treatment group)
Number of subjects: 69
Study: 23120733

Group type: EXPERIMENTAL
Intervention: Monopolar cautery
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bipolar cautery
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High frequency monopolar cautery
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High frequency bipolar cautery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study: 17870226

Group type: EXPERIMENTAL
Intervention: Blood glucose levels in quartile I (QI) 100 mg/dl
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Blood glucose levels in quartile II (QII) 130 mg/dl
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Blood glucose levels in quartile III (QIII) 162 mg/dl
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Blood glucose levels in quartile I (QI) 100 mg/dl after adjustment for confounders
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Blood glucose levels in quartile II (QII) 130 mg/dl after adjustment for confounders
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Blood glucose levels in quartile III (QIII) 162 mg/dl after adjustment for confounders
Number of subjects: 234
Study: 15830722

Group type: EXPERIMENTAL
Intervention: 3A Ofteno (Diclofenac sodium mixed with Sophisen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modusik-A Ofteno (Cyclosporine-A mixed with Sophisen)
Number of subjects: 0
Study: 12458653

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg + HCTZ 12.5 mg
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg + HCTZ 25 mg
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg + other antihypertensive +/- HCTZ (12.5 or 25 mg)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 690
Study: 10378365

Group type: EXPERIMENTAL
Intervention: Pouch reconstruction with preservation of the duodenal passage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reconstruction with a small jejunal pouch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Roux-en-Y-reconstruction without pouch
Number of subjects: 0
Study: 8724536

Group type: EXPERIMENTAL
Intervention: 5-day intravenous infusions of 2-CdA
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 7-day courses of 2-CdA
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: intermittent 2-hour infusions of 2-CdA
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: continuous 24-hour infusion of 2-CdA
Number of subjects: 41
Study: 1770128

Group type: EXPERIMENTAL
Intervention: Intranasal buserelin 200 micrograms four hourly for 21 days
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Subcutaneous buserelin 500 micrograms twice a day for 7 days, followed by 500 micrograms daily for 14 days
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Subcutaneous buserelin 500 micrograms three times a day for 7 days
Number of subjects: 33

Group type: COMPARATOR
Intervention: All groups (I, II, III)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 33
Study: 6761186

Group type: EXPERIMENTAL
Intervention: Aspirin 330 mg
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Aspirin 330 mg + Dipyridamole 75 mg three times daily
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 29796934

Group type: EXPERIMENTAL
Intervention: Allogenic bone marrow-derived mesenchymal stromal cells (BM-MSCs) by intrathecal infusion (1×10^6 cells/kg body weight, four infusions once a week)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 118
Study: 28973311

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) with bevacizumab, prescribed dose escalated from 18 to 22 Gy, single dose of bevacizumab given prior to SRS and continued until progression.
Number of subjects: 9
Study: 26919233

Group type: EXPERIMENTAL
Intervention: Catastrophizing (measured by Pain Catastrophizing Scale)
Number of subjects: 25
Study: 24687108

Group type: EXPERIMENTAL
Intervention: Social cognition and interaction training (SCIT) with social mentoring
Number of subjects: 55

Group type: COMPARATOR
Intervention: Social mentoring only
Number of subjects: 55
Study: 23198926

Group type: EXPERIMENTAL
Intervention: Instrument set A
Number of subjects: 14

Group type: COMPARATOR
Intervention: Instrument set B
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pattern-cutting task (using scissors and graspers)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Peg transfer task (using 2 graspers)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ligature loop task (using 1 grasper and 1 pretied ligature loop)
Number of subjects: 14
Study: 20937186

Group type: EXPERIMENTAL
Intervention: Baseline BMI < 17 kg/m(2)
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Baseline BMI
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Change in BMI from baseline to Year 1
Number of subjects: 979
Study: 17563195

Group type: EXPERIMENTAL
Intervention: Telephone assessments using the Penn State Worry Questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone assessments using the Beck Depression Inventory‐‐II
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone assessments
Number of subjects: 0
Study: 17071161

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (45 minutes, 5 days per week for 12 months)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (once-weekly, 45-minute stretching sessions)
Number of subjects: 115
Study: 11823389

Group type: EXPERIMENTAL
Intervention: Continued antidepressants before surgery (Group A, n=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Discontinued antidepressants 72 hr before surgery (Group B, n=40)
Number of subjects: 80
Study: 10449701

Group type: EXPERIMENTAL
Intervention: 8-mm tip electrode catheter
Number of subjects: 104

Group type: COMPARATOR
Intervention: 4-mm tip electrode catheter
Number of subjects: 104
Study: 8545533

Group type: EXPERIMENTAL
Intervention: Lorazepam (LZ)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Flumazenil (FL)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 48
Study: 1971991

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) (3.4 g/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Linoleic acid (14.3 g/d)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (9.2 g/d)
Number of subjects: 33
Study: 375690

Group type: EXPERIMENTAL
Intervention: Zinc sulfate, 0.2 g three times daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30636639

Group type: EXPERIMENTAL
Intervention: Airway Scope (AWS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Macintosh Laryngoscope (ML)
Number of subjects: 40
Study: 28675897

Group type: EXPERIMENTAL
Intervention: Individual Health Management (IHM) program for 1 year
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Self-monitoring of daily lifestyle
Number of subjects: 67
Study: 25466100

Group type: EXPERIMENTAL
Intervention: Tomato sauce (with refined olive oil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Raw tomatoes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tomato sauce (without refined olive oil)
Number of subjects: 0
Study: 22874090

Group type: EXPERIMENTAL
Intervention: Mindfulness-based pain management program (8 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Treatment-as-usual (control group)
Number of subjects: 28
Study: 21081764

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 19686525

Group type: EXPERIMENTAL
Intervention: Slow-release oral morphine (SROM)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Slow-release oral morphine (SROM) and Methadone
Number of subjects: 202
Study: 17464273

Group type: EXPERIMENTAL
Intervention: Back education program (13 hours over 2 school years)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Obligatory curriculum (no back education)
Number of subjects: 398
Study: 14871286

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Lansoprazole 15 mg
Number of subjects: 44
Study: 11702917

Group type: EXPERIMENTAL
Intervention: High intensity cycling (maximal 90-second sprint)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-intensity cycling (60 rpm equated for total work)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No exercise (control bout)
Number of subjects: 10
Study: 10784465

Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg/day)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Nortriptyline (25-100 mg/day)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 210

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 210
Study: 8627437

Group type: EXPERIMENTAL
Intervention: Investigational pneumococcal conjugate vaccine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Licensed pneumococcal polysaccharide vaccine (given as a booster)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Licensed pneumococcal polysaccharide vaccine (given as a primary injection to control group)
Number of subjects: 25
Study: 1456565

Group type: EXPERIMENTAL
Intervention: 0.12 ppm O3 (steady-state)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Triangular exposure pattern (0.24 ppm O3)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Steady-state O3 exposure
Number of subjects: 23

Group type: COMPARATOR
Intervention: Air exposure (control)
Number of subjects: 23
Study: 6324710

Group type: EXPERIMENTAL
Intervention: Cimetidine (1,200 mg/day orally)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg/day orally)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Warfarin sodium (1.5 mg/kg)
Number of subjects: 11
Study: 28718985

Group type: EXPERIMENTAL
Intervention: Non-suicidal self-injury (NSSI)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Suicide attempts
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: NSSI frequency
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: NSSI severity
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Impulsivity and depression
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Relative increase in NSSI frequency and severity
Number of subjects: 107
Study: 29857165

Group type: COMPARATOR
Intervention: Deep dry needling (DDN) with no local twitch responses (LTRs) elicited (control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) with 4 local twitch responses (LTRs) elicited
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) with 6 local twitch responses (LTRs) elicited
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) until no more local twitch responses (LTRs) were elicited
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups receiving DDN
Number of subjects: 120